von Willebrand Factor Collagen-Binding Activity (vWF:CBA)
Von Willebrand factor collagen-binding activity assesses the ability of the vWF protein to bind to vascular wall collagen. This is an important primary hemostatic function indicator, as binding to collagen initiates platelet aggregation and clot formation at the site of vascular injury.
The study helps detect hereditary and acquired von Willebrand factor disorders.
Test composition:
• Material: venous blood (plasma)
• Method: enzyme immunoassay or coagulometric test using collagen
• Determined indicator: percentage of collagen-binding activity relative to normal
Mechanism of abnormalities: decrease — hereditary vWF defects (von Willebrand disease type 2), acquired defects, liver diseases, immune degradation.
Biomaterial: Venous blood (plasma)
• Submit blood fasting
• Avoid alcohol for 24 hours
• Avoid physical exertion and stress 30 minutes before the test
Medications:
• If taking anticoagulants, antiplatelet agents, hormonal medications, or potent drugs, inform the doctor before the test
Prescribed for:
• Suspected hereditary or acquired von Willebrand factor disorders
• Frequent or spontaneous bleeding (nosebleeds, gum bleeding, subcutaneous hemorrhages)
• Monitoring therapy for von Willebrand disease
• Before surgical procedures or after surgery
Recommended for:
• Patients with frequent or unusual bleeding
• People with hereditary predisposition to von Willebrand disease
• Patients before surgery or after injuries
Reference values depend on the laboratory method and are indicated on the result form.
Decreased activity indicates functional vWF deficiency. Abnormalities require comprehensive assessment by a physician together with the clinical picture.
If abnormalities are detected: hematologist, general practitioner, cardiologist.
